Transcription factor Nrf2 as a potential therapeutic target for COVID-19
Cell Stress and Chaperones, ISSN: 1355-8145, Vol: 28, Issue: 1, Page: 11-20
2023
- 9Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef7
- Captures12
- Readers12
- 12
Review Description
The coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome (SARS)–like coronavirus (SARS-CoV-2). Critically ill patients with SARS-COV-2 infection frequently exhibit signs of high oxidative stress and systemic inflammation, which accounts for most of the mortality. Antiviral strategies to inhibit the pathogenic consequences of COVID-19 are urgently required. The nuclear factor erythroid 2–related transcription factor (Nrf2) is a transcription factor that is involved in antioxidant and anti-inflammatory defense in several tissues and cells. This review tries to present an overview of the role of Nrf2 in the treatment of COVID-19.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1355814523000779; http://dx.doi.org/10.1007/s12192-022-01296-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142459639&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36417098; https://linkinghub.elsevier.com/retrieve/pii/S1355814523000779; https://dx.doi.org/10.1007/s12192-022-01296-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know